CRBU
Caribou Biosciences Inc
NASDAQ: CRBU · HEALTHCARE · BIOTECHNOLOGY
$1.88
-2.08% today
Updated 2026-04-30
Market cap
$205.84M
P/E ratio
—
P/S ratio
18.45x
EPS (TTM)
$-1.59
Dividend yield
—
52W range
$1 – $4
Volume
1.4M
Caribou Biosciences Inc (CRBU) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | $5.79M | $12.36M | $9.60M | $13.85M | $34.48M | $9.99M | $11.16M |
| Revenue growth (YoY) | — | +113.6% | -22.4% | +44.3% | +148.9% | -71.0% | +11.7% |
| Cost of revenue | $23.64M | $34.42M | $984000.00 | $3.64M | $3.52M | $3.93M | $3.65M |
| Gross profit | $5.79M | $-22.06M | $8.61M | $10.21M | $30.95M | $6.07M | $7.51M |
| Gross margin | 100.0% | -178.5% | 89.7% | 73.7% | 89.8% | 60.7% | 67.3% |
| R&D | $23.64M | $34.42M | $52.26M | $82.23M | $112.08M | $130.15M | $109.44M |
| SG&A | $16.46M | $14.06M | $24.32M | $38.02M | $38.46M | $46.46M | $37.91M |
| Operating income | $-34.30M | $-36.12M | $-66.98M | $-106.40M | $-116.06M | $-166.62M | $-136.19M |
| Operating margin | -592.7% | -292.2% | -697.8% | -768.2% | -336.6% | -1667.2% | -1220.5% |
| EBITDA | $-30.21M | $-35.21M | $-65.61M | $-95.71M | $-112.53M | $-162.69M | $-132.55M |
| EBITDA margin | -522.0% | -284.8% | -683.6% | -691.0% | -326.4% | -1627.9% | -1187.8% |
| EBIT | $-30.96M | $-36.11M | $-66.59M | $-99.35M | $-116.06M | $-166.62M | $-136.19M |
| Interest expense | $4000.00 | $20000.00 | $8000.00 | $8.54M | — | — | — |
| Income tax | — | — | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-23.43M | $-34.31M | $-66.92M | $-99.42M | $-102.07M | $-149.10M | $-148.13M |
| Net income growth (YoY) | — | -46.4% | -95.1% | -48.6% | -2.7% | -46.1% | +0.7% |
| Profit margin | -404.8% | -277.6% | -697.3% | -717.8% | -296.1% | -1491.9% | -1327.4% |